A Phase I/1b Study of Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Enzalutamide (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Adverse reactions
- 29 Aug 2017 Planned End Date changed from 1 Dec 2018 to 1 Mar 2019.
- 29 Aug 2017 Planned primary completion date changed from 1 Dec 2018 to 1 Mar 2018.
- 29 Aug 2017 Status changed from recruiting to active, no longer recruiting.